On the news front, Keyuan Pharmaceutical, which hit the 20cm daily limit up today, announced on October 21st that the company plans to issue shares and pay cash to 39 counterparties, including its controlling shareholder Linuo Investment Holding Group Co., Ltd. and indirect controlling shareholder Linuo Group Co., Ltd., to purchase its 99.42% stake in Shandong Hongjitang Pharmaceutical Group Co., Ltd. At the same time, the company plans to issue shares to no more than 35 specific eligible individuals to raise matching funds. The total amount of matching funds raised in this round shall not exceed 100% of the transaction price for purchasing assets through the proposed issuance of shares, and the number of shares issued shall not exceed 30% of the total share capital of the listed company after the completion of the issuance of shares and the payment of cash to purchase assets. The issuance quantity and price shall be determined in accordance with relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

 

 

 

The main business of Hongjitang is the R&D, production and sales of traditional Chinese patent medicines and simple preparations, ass hide glue products, musk ketone and other products, with strong brand advantages and sales channel resources. Keyuan Pharmaceutical said that after the completion of this transaction, the company's main business will be extended to traditional Chinese patent medicines and simple preparations, ass hide glue products and other fields, realizing the intensive use of some production and office facilities and the coordination of procurement and sales channels.

 

 

 

It is worth noting that the stock price of Changshan Pharmaceutical has reached a new high today. As of 10:31, Changshan Pharmaceutical's increase was 15.12%, with a quoted price of 25.20 yuan, a transaction volume of 1.798 billion yuan, and a turnover rate of 8.26%.

 

 

 

It is understood that Changshan Pharmaceutical is a concept stock for weight loss drugs, but the company has repeatedly announced that its products do not involve obesity indications. On October 21st, Changshan Pharmaceutical issued a stock trading anomaly announcement, stating that the company's stock had accumulated a deviation of over 30% from the closing price increase for three consecutive trading days (October 16th, October 17th, and October 18th, 2024).

 

 

 

Changshan Pharmaceutical stated that in response to this situation, the company has verified the relevant matters and there is no need to correct or supplement the information disclosed earlier; No significant undisclosed information that may or has had a significant impact on the trading price of the company's stock has been reported recently; The company's recent business operations have been normal, with no changes in its main business and no significant changes in its internal and external operating environment; The company, controlling shareholder, and actual controller do not have any undisclosed major issues related to the company that should be disclosed, nor do they have any undisclosed major issues related to the company in the planning stage; The controlling shareholder and actual controller of the company did not engage in buying or selling of the company's stocks during periods of abnormal fluctuations in stock trading.

 

 

 

In addition, the company said that the clinical trials of albenatide and the marketing license it applied to the State Food and Drug Administration were all for the treatment of type 2 diabetes, not for obesity. The company has not yet conducted clinical trials of Ebenapeptide for obesity or weight loss. The company has no revenue related to weight loss products.

 

 

 

The company's Ebenapeptide injection has not yet been launched for sale. The application for marketing authorization of Albenatide Injection has been accepted by the National Medical Products Administration and is currently in the professional review stage. There is still uncertainty about whether Albenatide can be approved for marketing and the approval time. There are many kinds of drugs to treat type 2 diabetes, and GLP-1RA is one of them. Even if albenatide goes on the market in the future, it will also face high market competition risks, and its profitability is uncertain. Abenatide is a research and development registration mainly conducted by Changshan Kaijiejian, a subsidiary of the company. The company holds 51% of the shares of Changshan Kaijiejian, and the share of its net profit enjoyed by shareholders of the listed company is 51%, and the share enjoyed by minority shareholders is 49%. After Changshan Kaijiejian achieves profitability in the future, the company cannot enjoy all of its net profits.

 

 

 

For the pharmaceutical sector, Xinda Securities pointed out that the market has entered a period of oscillation and adjustment after experiencing significant fluctuations before the holiday. In the short term, companies will gradually disclose their 2024 third quarter reports in October, and it is recommended to pay attention to individual stocks whose performance is expected to exceed expectations; In the medium to long term, on the one hand, with the normalization of medical anti-corruption and centralized procurement, the marginal impact of policy events on pharmaceutical companies is gradually decreasing, and the performance of excellent enterprises with outstanding innovation capabilities is expected to recover first; On the other hand, benefiting from the series of fiscal stimulus measures such as local government bonds and real estate support, investment and financing are expected to rebound, residents' confidence is expected to gradually recover, and upstream assets in the innovative industrial chain and consumer medical enterprises are expected to benefit.